

## MediWound to Host Third Quarter 2018 Financial Results Conference Call on November 13 at 8:30 a.m. Eastern Time

November 7, 2018

YAVNE, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the third quarter ended September 30, 2018 at 8:30 am Eastern Time on Tuesday, November 13, 2018.

Following the release, MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. Eastern Time to discuss the financial results and to answer questions.

Shareholders and other interested parties may participate in the conference call by dialing 800-289-0438 (in the U.S.) 1809-212-883 (Israel), or 323-794-2423 (outside the U.S. & Israel) and entering passcode 8091639. The call also will be broadcast live on the Internet on the Company's website at <a href="http://ir.mediwound.com/events-and-presentations">http://ir.mediwound.com/events-and-presentations</a>.

A replay of the call will be accessible two hours after its completion through November 27, 2018 by dialing 844-512-2921 (in the U.S.) or 412-317-6671 (outside the U.S.) and entering passcode 8091639. The call will also be archived on the Company website for 90 days at <a href="https://www.mediwound.com">www.mediwound.com</a>.

## About MediWound Ltd.

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid®, received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian and South Korean Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns. NexoBrid® represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissues.

MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®. In two Phase 2 studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications.

For more information, please visit www.mediwound.com.

## Contacts:

Sharon Malka
Chief Financial and Operations Officer
MediWound
<a href="mailto:sharon@mediwound.com">sharon@mediwound.com</a>

Jeremy Feffer
Managing Director
LifeSci Advisors, LLC
ieremy@LifeSciAdvisors.com



Source: MediWound Ltd.